Artizan Biosciences reports that the U.S. Patent and Trademark Office has issued a patent that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform.
Artizan’s IgA-SEQ platform allows the company to interrogate microbial communities and identify individual bacterial strains and key virulence factors that elicit immunologic dysregulation and promote chronic inflammation.
Artizan then develops small molecule and biologic therapeutics that inhibit these targets and thereby disrupt the root causes of pathological inflammatory cascades.